The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease Inhibitors
Abstract
Background —Administration of protease inhibitors (PIs) to HIV-infected individuals has been associated with hyperlipidemia. In this study, we characterized the lipoprotein profile in subjects receiving ritonavir, indinavir, or nelfinavir, alone or in combination with saquinavir. Methods and Results —Plasma lipoprotein levels were quantified in 93 HIV-infected adults receiving PIs. Comparison was done with pretreatment values and with 28 nonPI-treated HIV-infected subjects. An elevation in plasma cholesterol levels was observed in all PI-treated groups but was more pronounced for ritonavir (2.0±0.3 mmol/L [mean±SEM], n=46, versus 0.1±0.2 mmol/L in nonPI treated group, P <0.001) than for indinavir (0.8±0.2 mmol/L, n=26, P =0.03) or nelfinavir (1.2±0.2 mmol/L, n=21, P =0.01). Administration of ritonavir, but not indinavir or nelfinavir, was associated with a marked elevation in plasma triglyceride levels (1.83±0.46 mmol/L, P =0.002). Plasma HDL-cholesterol levels remained unchanged. Combination of ritonavir or nelfinavir with saquinavir did not further elevate plasma lipid levels. A 48% increase in plasma levels of lipoprotein(a) was detected in PI-treated subjects with pretreatment Lp(a) values >20 mg/dL. Similar changes in plasma lipid levels were observed in 6 children receiving ritonavir. Conclusions —Administration of PIs to HIV-infected individuals is associated with a marked, compound-specific dyslipidemia. The risk of pancreatitis and premature atherosclerosis due to PI-associated dyslipidemia remains to be established.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D. J., & Cooper, D. A. (1998) · AIDS · doi:10.1097/00002030-199807000-00003 · Cited by 2,370
The mysteries of lipoprotein(a).
Utermann, G. (1989) · Science · doi:10.1126/science.2530631 · Cited by 1,257
Carr, A., Samaras, K., Chisholm, D. J., & Cooper, D. A. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03391-1 · Cited by 1,065
Boerwinkle, E., Leffert, C. C., Lin, J., Lackner, C., Chiesa, G., & Hobbs, H. H. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115855 · Cited by 962
Egger, M., Hirschel, B., Francioli, P., Sudre, P., Wirz, M., Flepp, M., Rickenbach, M., Malinverni, R., Vernazza, P., & Battegay, M. (1997) · BMJ · doi:10.1136/bmj.315.7117.1194 · Cited by 615
Self-citationAssmann, G., Schulte, H., & von Eckardstein, A. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00159-2 · Cited by 447
Marcovina, S. M., Albers, J. J., Gabel, B., Koschinsky, M. L., & Gaur, V. P. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.2.246 · Cited by 354
Self-citationEffects of Lowering Elevated LDL Cholesterol on the Cardiovascular Risk of Lipoprotein(a)
Maher, V. M. G. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530220037029 · Cited by 298
Vascular complications associated with use of HIV protease inhibitors
Gallet, B., Pulik, M., Genet, P., Chedin, P., & Hiltgen, M. (1998) · The Lancet · doi:10.1016/s0140-6736(05)78643-8 · Cited by 253
Protease inhibitor-associated hyperglycaemia
Dubé, M. P., Johnson, D. L., Currier, J. S., & Leedom, J. M. (1997) · The Lancet · doi:10.1016/s0140-6736(05)63513-1 · Cited by 241
Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities
Henry, K., Melroe, H., Huebesch, J., Hermundson, J., & Simpson, J. (1998) · The Lancet · doi:10.1016/s0140-6736(98)00022-1 · Cited by 207
Marked hyperlipidaemia on ritonavir therapy.
Sullivan, A., & Nelson, M. R. (1997) · PubMed · Cited by 108
Vascular complications associated with use of HIV protease inhibitors
Vittecoq, D., Escaut, L., & Jj, M. (1998) · The Lancet · doi:10.1016/s0140-6736(05)78644-x · Cited by 107
Kronenberg, F., Trenkwalder, E., Dieplinger, H., & Utermann, G. (1996) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.16.12.1568 · Cited by 106
Mooser, V., Marcovina, S. M., White, A. L., & Hobbs, H. H. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119055 · Cited by 95
Self-citation
Cited by
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
Triant, V. A., Lee, H., Hadigan, C., & Grinspoon, S. K. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2190 · Cited by 1,613
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Friis-Møller, N., Weber, R., Reiss, P., Thiébaut, R., Kirk, O., Monforte, A. D., Pradier, C., Morfeldt, L., Mateu, S., Law, M., et al. (2003) · AIDS · doi:10.1097/00002030-200305230-00010 · Cited by 1,077
Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults
Grinspoon, S., & Carr, A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041811 · Cited by 1,070
Metadata
- Authors
- Périard, D., Telenti, A., Sudre, P., Cheseaux, J.-J., Halfon, P., Reymond, M. J., Marcovina, S. M., Glauser, M. P., Nicod, P., Darioli, R., & Mooser, V.
- Venue
- Circulation
- Published
- 1999-08-17
- Volume
- 100
- Issue
- 7
- Pages
- 700-705
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2136385005
- Cited by
- 605
- References
- 15
- FWCI
- 56.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.